Rates of suicide have increased significantly over the past two decades, particularly among youth. Compared to the general population, autistic people are significantly more likely to think about suicide, attempt suicide, and die by suicide. Autistic individuals have identified suicide prevention as a top research priority; however, little is known about how to best help autistic youth at risk for suicide. The purpose of this study is to compare the effectiveness, feasibility, and acceptability of two suicide prevention strategies tailored for autistic individuals: the Safety Planning Intervention tailored for Autistic individuals (SPI-A) and SPI-A plus structured follow-up contacts (SPI-A+).
Suicidal Ideation, Suicidal and Self-injurious Behavior, Suicide, Autism Spectrum Disorder
Rates of suicide have increased significantly over the past two decades, particularly among youth. Compared to the general population, autistic people are significantly more likely to think about suicide, attempt suicide, and die by suicide. Autistic individuals have identified suicide prevention as a top research priority; however, little is known about how to best help autistic youth at risk for suicide. The purpose of this study is to compare the effectiveness, feasibility, and acceptability of two suicide prevention strategies tailored for autistic individuals: the Safety Planning Intervention tailored for Autistic individuals (SPI-A) and SPI-A plus structured follow-up contacts (SPI-A+).
A Comparison of Two Brief Suicide Prevention Interventions Tailored for Youth on the Autism Spectrum
-
Kennedy Krieger Institute, Baltimore, Maryland, United States, 21113
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27510
Nationwide Children's Hospital, Columbus, Ohio, United States, 43205
Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to 99 Years
ALL
No
University of North Carolina, Chapel Hill,
Danielle Roubinov, PhD, PRINCIPAL_INVESTIGATOR, University of North Carolina, Chapel Hill
Shari Jager-Hyman, PhD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania
2026-09